Text Size

A Retrospective Pharmacoeconomic Study of Lung Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2010 by Taipei Medical University WanFang Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier:
NCT01140958
First received: June 8, 2010
Last updated: June 9, 2010
Last verified: June 2010
History of Changes
  Purpose

Lung cancer is the No. cause of cancer death in Taiwan. Yet most of lung cancer are diagnosed at late stage, not amenable to surgical resection. With the introduction of new targeted agents, such as EGFR tyrosine kinase inhibitors and the identification of EGFR mutations, lung cancer management has markedly changed in recent years. However, these new agents are costly and their payment is restricted in certain situations defined National Insurance Agency. Therefore, using databases from National Insurance Agency might not be able to reflect the exact impact on pharmacoeconomics. In this study, the investigators will analyze the data from a tertiary medical center, where all the costs including insurance reimbursement, co-payment, and payment not covered by insurance. The investigators will also compare with the investigators results with national database to analyze the cost benefit of these new agents on lung cancer.


Condition
Lung Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A Retrospective Pharmacoeconomic Study of Lung Cancer in Wan-Fang Hospital

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by Taipei Medical University WanFang Hospital:

Enrollment: 91
Study Start Date: March 2008
Estimated Study Completion Date: November 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

lung cancer patients in WanFang Hospital

Criteria

Inclusion Criteria:

  • lung cancer patients in WanFang Hospital

Exclusion Criteria:

  • non
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01140958

Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Investigators
Principal Investigator: Hsin-Gjin Eugene Liu Taipei Medical University WanFang Hospital
  More Information

No publications provided

Responsible Party: Hsingjin Eugene Liu, MD PhD, Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier: NCT01140958     History of Changes
Other Study ID Numbers: Pharmacoeconomic-01
Study First Received: June 8, 2010
Last Updated: June 9, 2010
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Medical University WanFang Hospital:
lung cancer
pharmacoeconomics
new agents

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
 Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 16, 2013